What is CALITHERA BIOSCIENCES INC's earnings per share (EPS)?

CALITHERA BIOSCIENCES INC (CALA) reported diluted earnings per share of -$7.94 for fiscal year 2022. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CALITHERA BIOSCIENCES INC (CALA) Financials

CALA

FY2022 annual

Net Income -$39.6M +65.5% YoY

EPS (Diluted) -$7.94 YoY not available

Free Cash Flow -$43.7M +34.2% YoY

Operating Cash Flow -$43.6M +34.2% YoY

Market Cap $24K as of Oct 7, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2022

Price / Book 0.0x on $20.4M equity, Q4 FY2022

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2022, ended Dec 31, 2022 Reported Mar 31, 2023 Currency USD FYE December

Newest figures come from the 10-K for FY2022, filed Mar 31, 2023. Each column of the statement tables below links to the filing it was taken from.

This page shows CALITHERA BIOSCIENCES INC (CALA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CALA FY2022 2026-10-03

This remains a development-stage business: research spending exceeds reported revenue, while losses consume cash and financing reshapes the balance sheet.

From FY2021 to FY2022, the net loss narrowed from $115.1M to $39.7M, but operating cash outflow still totaled $43.6M in FY2022. The close relationship between earnings losses and cash use indicates that improvement came mainly from lower operating costs, not from a large noncash accounting adjustment.

The operating model is still research-led: FY2021 revenue of $9.8M was below $53.5M of R&D, so reported sales were not yet funding the research program. FY2022 R&D fell to $28.5M alongside the smaller loss, making reduced spending a major part of the improvement rather than evidence of a mature revenue engine.

The balance sheet changed more sharply than operations: total liabilities fell from $56.4M in FY2021 to $8.3M in FY2022, materially reducing leverage. Yet the current ratio slipped from 4.4x to 3.6x while operating cash flow remained negative, so the cleaner leverage profile coincided with a smaller asset base and continuing cash needs.

Financial Health Signals

Financial health score not available

CALITHERA BIOSCIENCES INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

CALITHERA BIOSCIENCES INC passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

CALITHERA BIOSCIENCES INC reported a net loss of $39.6M while operations used $43.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EPS (Diluted)

-$1.44

QoQ+28.4%

CALITHERA BIOSCIENCES INC earned -$1.44 per diluted share (EPS) in Q4 2022. Against the prior quarter it is up 28.4%.

Revenue

Not reported for Q4 2022.

EBITDA

Not reported for Q4 2022.

Net Income

Not reported for Q4 2022.

Cash & Balance Sheet

Free Cash Flow

-$8.6M

YoY+66.3%

QoQ-11.4%

CALITHERA BIOSCIENCES INC recorded an outflow of $8.6M in free cash flow in Q4 2022, representing a cash shortfall after capex. This represents an increase of 66.3% from the same quarter a year earlier. Against the prior quarter it is down 11.4%.

Cash & Debt

$25.5M

YoY-57.3%

QoQ-25.3%

5Y CAGR-12.1%

CALITHERA BIOSCIENCES INC held $25.5M in cash as of Q4 2022; long-term debt is not reported for that period.

Shares Outstanding

QoQ+0.1%

5Y CAGR-32.9%

CALITHERA BIOSCIENCES INC had 5M shares outstanding in Q4 2022. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q4 2022.

Margins & Returns

None of these metrics is reported for Q4 2022.

Capital Allocation

Capital Expenditures

$23K

YoY-41.0%

CALITHERA BIOSCIENCES INC invested $23K in capex in Q4 2022, funding long-term assets and infrastructure. This represents a decrease of 41.0% from the same quarter a year earlier.

R&D Spending

Not reported for Q4 2022.

Share Buybacks

Not reported for Q4 2022.

CALA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CALA quarterly income statement

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	N/A	$9.8M	N/A	N/A	$22.3M-14.3%	$26.0M	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$28.5M-46.6%	$53.5M-24.7%	$71.0M-6.9%	$76.3M+15.3%	$66.2M+53.5%	$43.1M+55.4%	$27.7M+16.8%	$23.7M+45.1%	$16.4M+65.3%	$9.9M+51.0%	$6.6M
SG&A Expenses	$13.5M-35.1%	$20.9M+2.4%	$20.4M+22.7%	$16.6M+24.5%	$13.3M+6.5%	$12.5M+18.4%	$10.6M+16.7%	$9.1M+69.4%	$5.4M+116.1%	$2.5M+74.9%	$1.4M
Operating Income	-$42.1M+63.6%	-$115.4M-26.3%	-$91.4M+1.6%	-$92.9M-62.2%	-$57.3M-93.0%	-$29.7M+22.6%	-$38.3M-16.8%	-$32.8M-51.1%	-$21.7M-75.5%	-$12.4M-55.2%	-$8.0M
EBITDA	-$41.8M+63.7%	-$115.1M-26.5%	-$91.0M+1.5%	-$92.4M-62.7%	-$56.8M-93.6%	-$29.3M+22.9%	-$38.0M-17.3%	-$32.4M-51.8%	-$21.4M-76.6%	-$12.1M-57.0%	-$7.7M
Interest Expense	N/A	N/A	N/A	N/A	$2.7M+42.6%	$1.9M+463.6%	$330K+88.6%	$175K+1844.4%	$9K+800.0%	$1K	N/A
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	-$39.6M+65.5%	-$115.1M-27.7%	-$90.1M-0.3%	-$89.9M-64.5%	-$54.6M-96.3%	-$27.8M+26.8%	-$38.0M-16.4%	-$32.6M-50.4%	-$21.7M-75.4%	-$12.4M-55.2%	-$8.0M
EPS (Basic)	-$4.60+85.2%	-$31.16-18.9%	-$26.20	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$7.94	-$31.16-18.9%	-$26.20	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	5M	4M+7.3%	3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K	Q3'2110-Q	Q2'2110-Q	Q1'2110-Q
Revenue	N/A	N/A	N/A	N/A	N/A	$6.8M	$3.0M	N/A
R&D Expenses	N/A	$6.4M-44.2%	$7.8M-39.5%	$9.6M-37.6%	N/A	$11.6M-36.4%	$12.8M-18.1%	$15.3M-23.8%
SG&A Expenses	N/A	$3.1M-51.5%	$3.6M-19.4%	$4.3M-21.5%	N/A	$6.3M+33.7%	$4.5M-12.0%	$5.4M+9.7%
Operating Income	N/A	-$9.5M+14.6%	-$11.4M+20.5%	-$13.8M+33.4%	N/A	-$11.2M+51.3%	-$14.3M+31.1%	-$20.8M+17.2%
EBITDA	N/A	-$9.5M+14.6%	-$11.3M+20.5%	-$13.8M+33.5%	N/A	-$11.1M+51.4%	-$14.2M+31.1%	-$20.7M+17.1%
Net Income	N/A	-$9.8M+12.3%	-$9.1M+36.6%	-$13.8M+32.2%	N/A	-$11.2M+50.9%	-$14.3M+29.8%	-$20.4M+16.6%
EPS (Basic)	-$1.45+92.2%	-$2.01+33.2%	$1.63+142.2%	N/A	-$18.67	-$3.01	-$3.86	N/A
EPS (Diluted)	-$1.44	-$2.01	-$1.59	N/A	-$18.67	-$3.01	-$3.86	N/A
Diluted Shares (Avg)	N/A	5M	6M	N/A	N/A	4M	4M	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

CALA Balance Sheet

CALA quarterly balance sheet

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$28.7M-55.7%	$64.8M-48.4%	$125.6M-25.6%	$168.8M+18.2%	$142.7M-25.8%	$192.5M+251.2%	$54.8M-27.7%	$75.8M-27.7%	$104.8M+200.7%	$34.8M	N/A
Current Assets	$26.6M-56.7%	$61.5M-48.2%	$118.7M-25.7%	$159.8M+13.9%	$140.3M-16.4%	$167.7M+213.0%	$53.6M-26.1%	$72.5M-30.2%	$103.9M+204.0%	$34.2M	N/A
Cash & Equivalents	$25.5M-57.3%	$59.5M-44.4%	$107.1M+77.3%	$60.4M+18.4%	$51.1M+5.3%	$48.5M+357.3%	$10.6M+73.6%	$6.1M-94.0%	$102.0M+201.5%	$33.8M+1433.8%	$2.2M
Short-Term Investments	$0	$0-100.0%	$8.0M-91.7%	$96.9M+13.9%	$85.1M-26.2%	$115.3M+180.0%	$41.2M-35.5%	$63.8M	$0	$0	$0
Accounts Receivable	N/A	N/A	$1.5M+219.7%	$482K-75.9%	$2.0M+74.9%	$1.1M	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0-100.0%	$22.4M	$0-100.0%	$2.0M	$0	$0	$0
Total Liabilities	$8.3M-85.3%	$56.4M+142.8%	$23.2M-11.9%	$26.3M+64.5%	$16.0M-62.0%	$42.1M+761.9%	$4.9M+23.4%	$4.0M-10.0%	$4.4M-92.1%	$55.7M	N/A
Current Liabilities	$7.4M-47.2%	$14.0M-23.9%	$18.4M-6.2%	$19.6M+31.9%	$14.9M-61.9%	$39.0M+776.4%	$4.5M+16.2%	$3.8M-7.0%	$4.1M+206.6%	$1.3M	N/A
Non-Current Liabilities	$894K-97.9%	$42.4M+779.9%	$4.8M-28.3%	$6.7M+494.5%	$1.1M-63.8%	$3.1M+614.2%	$437K+238.8%	$129K-54.4%	$283K+812.9%	$31K	N/A
Total Equity	$20.4M+143.3%	$8.4M-91.8%	$102.4M-28.1%	$142.4M+12.4%	$126.7M-15.7%	$150.3M+201.2%	$49.9M-30.5%	$71.8M-28.5%	$100.4M+582.2%	-$20.8M-142.8%	-$8.6M
Retained Earnings	-$512.6M-4.3%	-$491.3M-30.6%	-$376.2M-31.5%	-$286.1M-45.8%	-$196.2M-30.5%	-$150.3M-22.7%	-$122.5M-45.0%	-$84.5M-63.0%	-$51.9M-72.0%	-$30.1M	N/A

Metric	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K	Q3'2110-Q	Q2'2110-Q	Q1'2110-Q
Total Assets	$28.7M-55.7%	$37.1M-58.8%	$45.6M-53.4%	$50.2M-54.6%	$64.8M-48.4%	$90.0M-39.1%	$97.9M-40.7%	$110.7M-26.1%
Current Assets	$26.6M-56.7%	$34.7M-59.8%	$42.8M-54.4%	$47.3M-55.6%	$61.5M-48.2%	$86.3M-38.3%	$94.0M-40.0%	$106.5M-22.8%
Cash & Equivalents	$25.5M-57.3%	$34.1M-59.7%	$41.8M-54.7%	$44.7M-55.9%	$59.5M-44.4%	$84.5M-29.9%	$92.2M-19.7%	$101.4M+150.5%
Short-Term Investments	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$1.5M-98.4%
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$12K-97.4%	$12K-98.7%	$1.0M+5.3%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%
Total Liabilities	$8.3M-85.3%	$10.7M-31.2%	$10.3M-30.6%	$53.4M+223.5%	$56.4M+142.8%	$15.6M-38.1%	$14.8M-31.4%	$16.5M-25.0%
Current Liabilities	$7.4M-47.2%	$9.2M-31.8%	$8.9M-28.7%	$11.4M-17.5%	$14.0M-23.9%	$13.5M-31.7%	$12.5M-21.3%	$13.8M-12.4%
Non-Current Liabilities	$894K-97.9%	$1.5M-27.6%	$1.4M-40.3%	$42.0M+1451.4%	$42.4M+779.9%	$2.0M-61.9%	$2.4M-59.1%	$2.7M-56.8%
Total Equity	$20.4M+143.3%	$26.4M-64.5%	$35.3M-57.5%	-$3.1M-103.3%	$8.4M-91.8%	$74.4M-39.3%	$83.0M-42.1%	$94.2M-26.2%
Retained Earnings	-$512.6M-4.3%	-$505.7M-19.8%	-$495.9M-20.7%	-$505.2M-27.4%	-$491.3M-30.6%	-$422.1M-19.4%	-$410.9M-24.2%	-$396.6M-27.7%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

CALA Cash Flow Statement

CALA quarterly cash flow statement

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$43.6M+34.2%	-$66.3M+21.4%	-$84.3M-7.1%	-$78.7M-21.4%	-$64.8M-571.5%	$13.8M+144.3%	-$31.0M-3.6%	-$29.9M-55.6%	-$19.2M-62.5%	-$11.8M-69.3%	-$7.0M
Depreciation & Amortization	$300K0.0%	$300K-25.0%	$400K-20.0%	$500K-1.0%	$505K+38.4%	$365K+22.9%	$297K-26.5%	$404K+11.9%	$361K+28.5%	$281K+4.5%	$269K
Stock-Based Compensation	$4.0M-60.7%	$10.3M+27.3%	$8.1M+24.7%	$6.5M-13.1%	$7.4M+34.3%	$5.5M+30.3%	$4.3M+29.9%	$3.3M+374.9%	$689K+884.3%	$70K+125.8%	$31K
Capital Expenditures	$133K-9.5%	$147K+141.0%	$61K+771.4%	$7K-96.7%	$214K-82.6%	$1.2M+206.5%	$401K-9.1%	$441K-20.7%	$556K+239.0%	$164K+234.7%	$49K
Free Cash Flow	-$43.7M+34.2%	-$66.4M+21.2%	-$84.4M-7.1%	-$78.8M-21.1%	-$65.1M-619.5%	$12.5M+139.8%	-$31.4M-3.5%	-$30.4M-53.5%	-$19.8M-64.9%	-$12.0M-70.5%	-$7.0M
Investing Cash Flow	-$133K-101.7%	$7.9M-91.2%	$89.0M+924.9%	-$10.8M-120.4%	$52.8M+153.6%	-$98.4M-515.2%	$23.7M	N/A	N/A	N/A	N/A
Financing Cash Flow	$9.7M-9.5%	$10.7M-74.6%	$42.1M-57.5%	$98.9M+576.2%	$14.6M-88.1%	$122.9M+940.5%	$11.8M	N/A	N/A	N/A	N/A

Metric	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K	Q3'2110-Q	Q2'2110-Q	Q1'2110-Q
Operating Cash Flow	-$8.6M+66.4%	-$7.7M-1.7%	-$11.3M-1.3%	-$16.0M+27.2%	-$25.6M-11.2%	-$7.6M+53.3%	-$11.1M+38.2%	-$22.0M+18.6%
Depreciation & Amortization	N/A	$62K-10.1%	$64K-12.3%	$64K-12.3%	N/A	$69K-19.8%	$73K-19.8%	$73K-30.5%
Stock-Based Compensation	N/A	N/A	N/A	$1.2M-56.2%	N/A	N/A	N/A	$2.7M+35.2%
Capital Expenditures	$23K-41.0%	$0	N/A	N/A	$39K+8.3%	N/A	N/A	N/A
Free Cash Flow	-$8.6M+66.3%	-$7.7M	N/A	N/A	-$25.6M-11.2%	N/A	N/A	N/A
Investing Cash Flow	-$23K+41.0%	$0+100.0%	N/A	N/A	-$39K-100.4%	-$108K-100.5%	$1.5M-97.4%	$6.5M+1158.6%
Financing Cash Flow	$4K-99.4%	$15K+1400.0%	$8.5M+1689.3%	$1.1M-88.1%	$655K+31.0%	$1K-50.0%	$475K-98.6%	$9.5M+24.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CALA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CALA quarterly financial ratios

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Margin	N/A	-1183.9%	N/A	N/A	-257.4%	-114.4%	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	-1180.4%	N/A	N/A	-245.5%	-107.2%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-194.4%+1178.6pp	-1373.0%-1285.0pp	-88.0%-25.0pp	-63.1%-20.0pp	-43.1%-24.6pp	-18.5%+57.6pp	-76.1%-30.7pp	-45.5%-23.8pp	-21.6%	N/A	N/A
Return on Assets	-138.3%+39.5pp	-177.7%-106.0pp	-71.8%-18.5pp	-53.2%-15.0pp	-38.3%-23.8pp	-14.5%+54.9pp	-69.4%-26.3pp	-43.1%-22.4pp	-20.7%+14.8pp	-35.5%	N/A
Current Ratio	3.60-0.8x	4.39-2.1x	6.45-1.7x	8.14-1.3x	9.42+5.1x	4.30-7.7x	12.03-6.9x	18.91-6.3x	25.20-0.2x	25.42	N/A
Debt-to-Equity	0.41-6.3x	6.73+6.5x	0.230.0x	0.18+0.1x	0.13-0.2x	0.28+0.2x	0.100.0x	0.060.0x	0.04	N/A	N/A
Asset Turnover	N/A	0.15	N/A	N/A	0.160.0x	0.13	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	-681.5%	N/A	N/A	-292.3%	48.3%	N/A	N/A	N/A	N/A	N/A

Metric	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K	Q3'2110-Q	Q2'2110-Q	Q1'2110-Q
Operating Margin	N/A	N/A	N/A	N/A	N/A	-165.2%	-476.9%	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	-165.5%	-477.0%	N/A
Return on Equity	N/A	-37.1%-22.1pp	-25.8%-8.5pp	N/A	N/A	-15.0%+3.5pp	-17.2%-3.0pp	-21.7%-2.5pp
Return on Assets	N/A	-26.4%-14.0pp	-19.9%-5.3pp	-27.5%-9.1pp	N/A	-12.4%+3.0pp	-14.6%-2.3pp	-18.4%-2.1pp
Current Ratio	3.60-0.8x	3.76-2.6x	4.81-2.7x	4.16-3.6x	4.39-2.1x	6.38-0.7x	7.53-2.3x	7.72-1.0x
Debt-to-Equity	0.41-6.3x	0.41+0.2x	0.29+0.1x	N/A	6.73+6.5x	0.210.0x	0.180.0x	0.180.0x
Asset Turnover	N/A	N/A	N/A	N/A	N/A	0.07	0.03	N/A

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Where CALITHERA BIOSCIENCES INC Ranks

Frequently Asked Questions

Is CALITHERA BIOSCIENCES INC profitable?

No, CALITHERA BIOSCIENCES INC (CALA) reported a net income of -$39.6M in fiscal year 2022.

What is CALITHERA BIOSCIENCES INC's EBITDA?

CALITHERA BIOSCIENCES INC (CALA) had EBITDA of -$41.8M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

What is CALITHERA BIOSCIENCES INC's return on equity (ROE)?

CALITHERA BIOSCIENCES INC (CALA) has a return on equity of -194.4% for fiscal year 2022, measuring how efficiently the company generates profit from shareholder equity.

What is CALITHERA BIOSCIENCES INC's free cash flow?

CALITHERA BIOSCIENCES INC (CALA) recorded an outflow of $43.7M in free cash flow during fiscal year 2022. This represents a 34.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is CALITHERA BIOSCIENCES INC's operating cash flow?

CALITHERA BIOSCIENCES INC (CALA) recorded an outflow of $43.6M in operating cash flow during fiscal year 2022, representing cash used by core business activities.

What are CALITHERA BIOSCIENCES INC's total assets?

CALITHERA BIOSCIENCES INC (CALA) had $28.7M in total assets as of fiscal year 2022, including both current and long-term assets.

What are CALITHERA BIOSCIENCES INC's capital expenditures?

CALITHERA BIOSCIENCES INC (CALA) invested $133K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.

How much does CALITHERA BIOSCIENCES INC spend on research and development?

CALITHERA BIOSCIENCES INC (CALA) invested $28.5M in research and development during fiscal year 2022.

How many shares does CALITHERA BIOSCIENCES INC have outstanding?

CALITHERA BIOSCIENCES INC (CALA) had 5M shares outstanding as of fiscal year 2022.

What is CALITHERA BIOSCIENCES INC's current ratio?

CALITHERA BIOSCIENCES INC (CALA) had a current ratio of 3.60 as of fiscal year 2022, which is generally considered healthy.

What is CALITHERA BIOSCIENCES INC's debt-to-equity ratio?

CALITHERA BIOSCIENCES INC (CALA) had a debt-to-equity ratio of 0.41 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is CALITHERA BIOSCIENCES INC's return on assets (ROA)?

CALITHERA BIOSCIENCES INC (CALA) had a return on assets of -138.3% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.

What is CALITHERA BIOSCIENCES INC's P/E ratio?

CALITHERA BIOSCIENCES INC (CALA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2022). The market capitalization is $24K as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is CALITHERA BIOSCIENCES INC's price-to-sales ratio?

CALITHERA BIOSCIENCES INC (CALA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $24K as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is CALITHERA BIOSCIENCES INC's Piotroski F-Score?

CALITHERA BIOSCIENCES INC (CALA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are CALITHERA BIOSCIENCES INC's earnings high quality?

CALITHERA BIOSCIENCES INC (CALA) reported a net loss of $39.6M while operations used $43.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.